Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. louisa-3d

LOUISA-3D

Clinical validation of Laser Optoacoustic Ultrasonic 3D Imaging System Assembly for breast cancer detection and characterization through endogenous biomarkers.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 LOUISA-3D project word cloud

Explore the words cloud of the LOUISA-3D project. It provides you a very rough idea of what is the project "LOUISA-3D" about.

marked    magnetic    anatomical    detection    female    ionizing    effect    representing    bcs    media    measuring    treatment    neoadjuvant    international    population    overcome    commercializes    3d    bc    plan    imaging    release    manufactured    board    diagnostic    complete    louisa    oxygen    clinical    images    ultrasonic    affordable    view    commercialization    standard    trial    therapy    resonance    sensitivity    biomarkers    limitations    nat    characterization    mammography    first    tomography    cancer    content    deaths    safe    hemoglobin    ce    device    digital    market    commercialized    financial    functional    protocols    validate    enhanced    bios    evaluation    predictive    locally    capability    feasibility    screening    saturation    enter    coregistered    contrast    optoacoustic    blood    scientific    full    once    radiation    endogenous    laser    business    medical    recall    risk    breast    ultrasound    modality    company    validating    validated    worldwide    opportunity    positive    introducing    rate    resolution    women    committee    trials    assembly    exogenous    combines   

Project "LOUISA-3D" data sheet

The following table provides information about the project.

Coordinator		 BIOS S.R.L. 

Organization address
address: VIA GUIDO ROSSA, 10/12
city: VIMODROME
postcode: 20090
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Italy [IT]
 Project website https://ec.europa.eu/easme/en/sme/5478/clinical-validation-laser-optoacoustic-ultrasonic-3d-imaging-system-assembly-breast-cancer
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOS S.R.L. IT (VIMODROME) coordinator 50˙000.00

Map

 Project objective

Breast cancer (BC) is the most common cancer and the first cause of cancer-related deaths in European women. Laser Optoacoustic Ultrasonic 3D Imaging System Assembly (LOUISA-3D) combines optoacoustic functional information from endogenous biomarkers (hemoglobin content and blood oxygen saturation) with high-resolution anatomical images of ultrasound tomography, without the need for ionizing radiation or exogenous contrast media. The objective of LOUISA-3D is to overcome the main limitations of current imaging methods, by validating and introducing to the EU market a novel multi-modality diagnostic device for BC, based on coregistered full view 3D optoacoustic and ultrasonic technology. LOUISA-3D will be a highly effective, safe and affordable imaging method for BC detection, characterization, and evaluation of the effect of neoadjuvant therapy (NAT). Two clinical trials will validate LOUISA-3D. Trial 1 will measure detection rate, recall rate, sensitivity, and positive predictive value of LOUISA-3D as a screening test in a selected female population at increased risk for BC, as compared to standard digital mammography. Trial 2 will assess the LOUISA-3D endogenous biomarkers capability of measuring the NAT effect in the treatment of locally advanced BCs, as compared to contrast-enhanced magnetic resonance imaging. During this feasibility study, an international scientific committee will deliver both trial protocols, and a management board will release a work and financial plan for the trials and a business plan for the production and commercialization of LOUISA-3D, complete market analysis, cost analysis and financial plan. The applying company, Bios, commercializes medical laser systems worldwide. Once validated and CE medical marked, LOUISA-3D will be manufactured and commercialized in EU, representing an important opportunity for Bios to enter the medical imaging market and enable its significant growth.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LOUISA-3D" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LOUISA-3D" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More